Navelbine (Vinorelbine Tartrate)

Vinorelbine tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral dosage form for oral use. It is used to treat certain types of cancer, including non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine tartrate is employed in oncology to treat solid tumours that depend on microtubule dynamics.

- Non‑small cell lung cancer: helps control disease progression and may extend survival in adult patients. - Metastatic breast cancer: reduces tumour growth and alleviates disease‑related symptoms. - Advanced solid tumours (off‑label clinical practice): may be considered when other regimens are unsuitable.

Vinorelbine tartrate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Nausea and vomiting: gastrointestinal upset common after dosing. - Constipation: decreased bowel motility. - Alopecia: hair thinning or loss. - Fatigue: general tiredness during treatment.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection. - Pulmonary toxicity, including interstitial pneumonitis. - Peripheral neuropathy presenting as tingling or numbness. - Severe allergic reactions such as anaphylaxis. - Cardiac arrhythmias or conduction disturbances.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for toxicity. - Blood count monitoring: perform complete blood counts regularly to detect myelosuppression. - Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically. - Pulmonary evaluation: avoid use in patients with pre‑existing severe lung disease. - Concomitant myelosuppressive agents: use caution when combined with other chemotherapy that depresses bone marrow. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Vinorelbine tartrate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase vinorelbine plasma levels and toxicity. - Drugs that prolong QT interval: may raise the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic exposure. - Live vaccines: immunosuppression from vinorelbine may diminish vaccine efficacy.